USE OF ESMOLOL IN CONTROL OF HEMODYNAMIC RESPONSE

Objective & Hypothesis:Esmolol is a selective beta receptor blocker with rapid onset and short duration of action and inactivated free from liver and renal functions.

📊

Key Findings & Data:The increase in heart rate and blood pressure according to laryngoscopy and tracheal intubation can be controlled by esmolol.

💡

Conclusion & Impact:We aimed to review the clinical and pharmacological properties of this selective beta adrenergic receptor antagonist along with the literature.

🔬Design:Review & Systematic Survey

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Esmolol is a selective beta receptor blocker with rapid onset and short duration of action and inactivated free from liver and renal functions. It is used to prevent and treat arrhythmia, tachycardia and hypertension which is a result of beta adrenergic stimulation. The increase in heart rate and blood pressure according to laryngoscopy and tracheal intubation can be controlled by esmolol. We aimed to review the clinical and pharmacological properties of this selective beta adrenergic receptor antagonist along with the literature.

Özet

Esmolol etkisi hızlı başlayan ve çok kısa süreli olarak hepatik ve renal fonksiyonlardan bağımsız şekilde inaktive edilen selektif bir beta adrenerjik reseptör blokerdir. Klinik olarak beta adrenerjik stimülasyon sonucu oluşan aritmi, taşikardi ve hipertansiyon gibi adrenerjik yanıtların kontrol edilmesi amacıyla kullanılmaktadır. Literatürde laringoskopi ve trakeal entübasyona bağlı oluşan kalb hızı artışı ve hipertansif cevabın doz titrasyonu ile baskılanabileceği ifade edilmiştir. Bu derlemede, selektif bir beta adrenerjik reseptör antagonisti olan esmololün klinik ve farmakolojik özelliklerinin literatürler eşliğinde incelenmesi amaçlanmıştır.

🔖

Cite This Article

BAŞAR, H., ÖZCAN, A., ÖZCAN, N., AYDIN, M. A., KAYMAK, Ç. (2022). USE OF ESMOLOL IN CONTROL OF HEMODYNAMIC RESPONSE. Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 48 - Sayı: 3, 139–143. https://ajindex.com/articles/441400

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (1)

Sum CY, Yacobi A, Kartzinel R, et al. Kinetics of esmolol, an ultra-short acting beta-blocker, and of its major metabolite. Clin Pharmacol Ther. 1983; 34: 427. 2)Turlapaty P, Laddu A. Esmolol: a titratable short-acting inravenous beta blocker for acute critial care settings. Am Heart J. 1997; 114: 866- 885. 3)Bateman TM, Czer LSC. Esmolol: a new ultrashort-acting beta adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachy-arrhythmias. J Am Coll Cardiol. 1985; 5: 1451-1416. 4)Péréon Y, Bernard JM. The effects of desflurane on the nervous system: from spinal cord to muscles. Anesth Analg. 1999; 89: 490-495. 5)Braunwald E, Muller JE, Kloner RA, et al. Role of beta-adrenergic blockade in therapy of patients with myocardial infarction. Am J Med. 1983; 74: 113-118. 6)Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. Mortality results. JAMA. 1982; 247: 1707-1711. 7)Safwat AM, Rertan JA, Misle GR, et al. Use of propranolol to control rate pressure product during cardiac anesthesia. Anesth Analg. 1981; 60: 732-736. 8)Kaplan JA, Dunbar RW. Propranolol and surgical anesthesia. Anesth Analg. 1976; 55: 1-5. 9)Lowenthal DT, Porter RS, Saris RS, et al. Clinical pharmacology, pharmacodynamics, and interactions with esmolol. Am J Cardiol. 1985; 56: 14-18. 10)Kaplan JA. Role of ultrashort-acting beta-blokers in the perioperative period. Cardiothoracic Anesth. 1988; 2: 682-691. 11)Sinetos AL, Hulse J, Pritchett EL. Pharmacokinetics and pharmacodynamics of esmolol administered as an intravenous bolus. Clin Pharmocol Ther. 1987; 41; 112-117 12)Figueredo E, Garcia-Fuentes EM. Assessment of the efficacy of esmolol on the haemodynamic changes induced by laryngoscopy and tracheal intubation: a meta-analysis. Acta Anaesthesiol Scand. 2001; 45: 1011-1022. 13)Askenazi J, MacCosbe P, Hoff JV, et al. Hemodynamic effects of esmolol, a short acting beta blocker. J Clin Pharmacol. 1987; 27: 567-573. 14)Sheppard D, Distefano S, Byrd RC, et al. Effects of esmolol on airway function in patients with asthma. J Clin Pharmacol. 1986; 26: 169-175. 15)Abrams J, Allen J, Allin Deksmedetomidin, et al. Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: a multicenter double-blind clinical trial. Am Heart J. 1985; 110: 913-918. 16)Morganroth J, Horowitz LN, Anderson J, et al. Comparative efficacy and tolerance of esmolol to propran